Skip navigation.

GenPhar, Inc.
http://www.genphar.com
Short Header Picture 06

news

article

For Life

For Future

Publications

2006-04-05
GenPhar publishes Trivalent Marburg vaccine study.
"De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses."

Vaccine. 2006 Apr 5;24(15):2975-86. Epub 2005 Dec 9.

Click here for Pubmed Abstract link.

Vaccine website
About GenPhar, Inc.

GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina.

To learn more about GenPhar and its vaccine programs, please contact us.